Login to Your Account

Frontier's pain patch hits phase II endpoints

By Shannon Ellis
Staff Writer

Friday, June 24, 2016

SHANGHAI – A transdermal pain patch being studied by Frontier Biotechnologies Inc., of Nanjing, China, has met its primary endpoints in a U.S. phase II trial of 146 patients with chronic lower back pain.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription